HPS2-THRIVE Trial
Study / Research
The Heart Protection Study 2 to THRVIVE trial, a large cardiovascular outcomes trial that showed no cardiovascular benefits from niacin therapy.
Mentioned in 2 videos
Save the 2 videos on HPS2-THRIVE Trial to your own pod.
Sign up free to keep building your knowledge base on HPS2-THRIVE Trial as more episodes are added.
Videos Mentioning HPS2-THRIVE Trial
210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.
Peter Attia MD
The Heart Protection Study 2 to THRVIVE trial, a large cardiovascular outcomes trial that showed no cardiovascular benefits from niacin therapy.
407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more
Peter Attia MD
A study that showed Niacin on top of statins did not lower cardiovascular events, although some analysis suggested a benefit from LDL lowering.